JAAD International最新文献

英文中文

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study 局部1.5%鲁索替尼乳膏治疗面部难治性节段性白癜风：一项回顾性单中心研究

IF 5.2

JAAD International

Pub Date : 2025-10-03 DOI: 10.1016/j.jdin.2025.08.016

Hequn Huang MM , Dawei Duan MM , He Huang MD , Xianfa Tang MD , Caihong Zhu MD , Yaohua Zhang MD , Min Li MD , Yujun Sheng MD , Leihong Xiang MD, PHD , Yong Cui MD , Youwen Zhou MD , Xuejun Zhang MD, PHD , Bo Zhang MD, PHD

引用次数: 0

Chronic venous insufficiency increases postoperative complications after Mohs micrographic surgery for lower extremity nonmelanoma skin cancer: A propensity-matched retrospective cohort study 慢性静脉功能不全增加下肢非黑色素瘤皮肤癌莫氏显微摄影手术后并发症：一项倾向匹配的回顾性队列研究

IF 5.2

JAAD International

Pub Date : 2025-10-03 DOI: 10.1016/j.jdin.2025.09.008

Sahithi Talasila MD , Umer Nadir MD , George M. Jeha MD , Stanislav N. Tolkachjov MD

引用次数: 0

Bullous dermatologic reactions in immune checkpoint inhibitor therapy: A systematic review 免疫检查点抑制剂治疗中的大疱性皮肤反应：系统综述

IF 5.2

JAAD International

Pub Date : 2025-10-03 DOI: 10.1016/j.jdin.2025.08.015

Chinathip Theerawattanawit MD, Patcharapong Rujirawan MD, Pawinee Rerknimitr MD, MSc

引用次数: 0

Improvised drainage system for postoperative hematoma in resource-limited settings 资源有限地区术后血肿简易引流系统

IF 5.2

JAAD International

Pub Date : 2025-10-03 DOI: 10.1016/j.jdin.2025.09.009

Mitchell Hanson BS , Jennifer Easterly BS , David Harvey MD

引用次数: 0

Viral infections as triggers in autoimmune blistering diseases: A systematic review of associations and mechanisms 病毒感染作为自身免疫性水疱疾病的触发因素：关联和机制的系统综述

IF 5.2

JAAD International

Pub Date : 2025-10-03 DOI: 10.1016/j.jdin.2025.09.007

Henry Tseng , John W. Frew MBBS (Hons), MMed, MS, PhD , Dédée F. Murrell MA, BMBCh, MD, DSc

引用次数: 0

Combination secukinumab and surgical intervention for moderate-to-severe hidradenitis suppurativa: A retrospective cohort study 联合secukinumab和手术干预治疗中重度化脓性汗腺炎：一项回顾性队列研究

IF 5.2

JAAD International

Pub Date : 2025-10-02 DOI: 10.1016/j.jdin.2025.08.014

Qiuyun Xu MD , Yifan Xie MD , Zhuo Chen MD , Fang Fang MD , Shuyi Shen MD , Songyu Wang MD , Chengbei Bao MD , Ying Zou PhD , Dan Deng PhD , Chao Ji MD, PhD , Ting Gong PhD

引用次数: 0

Impact of sleep disturbance on mental health in schoolchildren with atopic dermatitis: A population-based study 睡眠障碍对小学生特应性皮炎心理健康的影响：一项基于人群的研究

IF 5.2

JAAD International

Pub Date : 2025-10-01 DOI: 10.1016/j.jdin.2025.08.013

Kan-Hsuan Lin MD , Yu-Jun Chang PhD , Tung-Ming Chang MD, PhD , Kuender D. Yang MD, PhD , Ching-Yuang Lin MD, PhD , Ko-Huang Lue MD, PhD , Hai-Lun Sun MD, PhD , Pei-Fen Liao MD , Jun-Kai Kao MD, PhD , Yi-Giien Tsai MD, PhD

Objective

This Taiwanese population-based cross-sectional (CARE) study examined associations between sleep disturbances and mental health symptoms in adolescents with atopic dermatitis (AD).

Method

A cross-sectional analysis was conducted among 14,675 adolescents (median age: 12.6 years; 49.7% male) using validated self-report questionnaires to assess anxiety (Screen for Child Anxiety Related Emotional Disorders) and depression (Patient Health Questionnaire-9). AD was identified via physician diagnosis and self-reported symptoms. Sleep quality, frequency of disturbances, and daytime sleepiness were evaluated using self-report. Logistic regression models adjusted for sex and psychosocial factors were used to assess associations with mental health outcomes.

Results

Adolescents with AD (n = 3470) had higher anxiety (18.7% vs 16.0%) and depression (4.2% vs 2.4%) prevalence than health controls (n = 7865) (P < 0.001). Among adolescents with AD, weekly sleep disturbances, poor sleep quality, and daytime sleepiness were independently associated with 2.1, 1.8, and 1.6-fold higher risks of anxiety and 4.4, 2.7, and 2.1-fold higher risks of depression, after adjustment for sex and psychosocial factors. A dose-response relationship was observed between the sleep disturbance frequency and symptom severity.

Conclusion

Sleep disturbances are strongly associated with increased anxiety and depression symptoms in adolescents with AD. Interventions focusing on sleep and psychosocial stress may improve mental health outcomes in this vulnerable population.

目的：本以台湾人口为基础的横断面（CARE）研究，探讨青少年特应性皮炎（AD）患者睡眠障碍与心理健康症状的关系。方法对14675名青少年（中位年龄12.6岁，男性49.7%）进行横断面分析，采用有效的自我报告问卷来评估焦虑（儿童焦虑相关情绪障碍筛查）和抑郁（患者健康问卷-9）。通过医生诊断和自我报告的症状来确定AD。使用自我报告评估睡眠质量、干扰频率和白天嗜睡。采用调整了性别和社会心理因素的逻辑回归模型来评估与心理健康结果的关联。结果阿尔茨海默症青少年（n = 3470）的焦虑（18.7% vs 16.0%）和抑郁（4.2% vs 2.4%）患病率高于健康对照组（n = 7865）（P < 0.001）。在患有阿尔茨海默病的青少年中，在调整性别和社会心理因素后，每周睡眠障碍、睡眠质量差和白天嗜睡与焦虑风险增加2.1倍、1.8倍和1.6倍以及抑郁风险增加4.4倍、2.7倍和2.1倍独立相关。睡眠障碍频率与症状严重程度呈剂量-反应关系。结论睡眠障碍与阿尔茨海默病青少年焦虑和抑郁症状的增加密切相关。关注睡眠和社会心理压力的干预措施可能会改善这一弱势群体的心理健康状况。

{"title":"Impact of sleep disturbance on mental health in schoolchildren with atopic dermatitis: A population-based study","authors":"Kan-Hsuan Lin MD , Yu-Jun Chang PhD , Tung-Ming Chang MD, PhD , Kuender D. Yang MD, PhD , Ching-Yuang Lin MD, PhD , Ko-Huang Lue MD, PhD , Hai-Lun Sun MD, PhD , Pei-Fen Liao MD , Jun-Kai Kao MD, PhD , Yi-Giien Tsai MD, PhD","doi":"10.1016/j.jdin.2025.08.013","DOIUrl":"10.1016/j.jdin.2025.08.013","url":null,"abstract":"<div><h3>Objective</h3><div>This Taiwanese population-based cross-sectional (CARE) study examined associations between sleep disturbances and mental health symptoms in adolescents with atopic dermatitis (AD).</div></div><div><h3>Method</h3><div>A cross-sectional analysis was conducted among 14,675 adolescents (median age: 12.6 years; 49.7% male) using validated self-report questionnaires to assess anxiety (Screen for Child Anxiety Related Emotional Disorders) and depression (Patient Health Questionnaire-9). AD was identified via physician diagnosis and self-reported symptoms. Sleep quality, frequency of disturbances, and daytime sleepiness were evaluated using self-report. Logistic regression models adjusted for sex and psychosocial factors were used to assess associations with mental health outcomes.</div></div><div><h3>Results</h3><div>Adolescents with AD (<em>n</em> = 3470) had higher anxiety (18.7% vs 16.0%) and depression (4.2% vs 2.4%) prevalence than health controls (<em>n</em> = 7865) (<em>P</em> < 0.001). Among adolescents with AD, weekly sleep disturbances, poor sleep quality, and daytime sleepiness were independently associated with 2.1, 1.8, and 1.6-fold higher risks of anxiety and 4.4, 2.7, and 2.1-fold higher risks of depression, after adjustment for sex and psychosocial factors. A dose-response relationship was observed between the sleep disturbance frequency and symptom severity.</div></div><div><h3>Conclusion</h3><div>Sleep disturbances are strongly associated with increased anxiety and depression symptoms in adolescents with AD. Interventions focusing on sleep and psychosocial stress may improve mental health outcomes in this vulnerable population.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"24 ","pages":"Pages 50-60"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145398510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From variant of unknown significance to actionable diagnosis: Stepwise interpretation of a novel KRT2 variant in superficial epidermolytic ichthyosis with excellent retinoid response 从未知意义的变异到可操作的诊断：逐步解释具有优异类视黄酮反应的浅表皮松解性鱼鳞病的一种新的KRT2变异

IF 5.2

JAAD International

Pub Date : 2025-10-01 DOI: 10.1016/j.jdin.2025.09.006

Alexandra Carla Bobica MSc, MD , Sarah Moussa MD , Lydia Ouchene MD , Megha Udupa MD , Hessah BinJadeed MBBS , Rahaf Bashihab MBBS , Zuzanna Misiewicz PhD , Laura Grönroos MSc , Julie Powell MD , May Chergui MD , Tania Cruz Marino MD, PhD , William D. Foulkes MBBS, PhD , Elena Netchiporouk MD, MSc

引用次数: 0

Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching 原发药与阿达木单抗治疗化脓性汗腺炎的生物仿制药：临床反应、反应维持和转换的多中心真实世界分析

IF 5.2

JAAD International

Pub Date : 2025-10-01 DOI: 10.1016/j.jdin.2025.05.023

Marra Aghajani MBBS, PhD , James Pham MD , Tara Sholji MBBS , Kate Burrell BSc , Cindy Kok MD, PhD , John W. Frew MBBS (Hons), MMed, MS, PhD

Background

Adalimumab is a mainstay treatment for hidradenitis suppurativa (HS); however, high-costs limit accessibility. While biosimilars offer an affordable alternative, concerns remain regarding clinical equivalence and the impact of switching.

Objective

To evaluate the clinical response of originator versus biosimilar adalimumab in HS and assess outcomes following nonmedical switching.

Methods

This multicenter, real-world study included treatment naïve HS patients initiated on originator or biosimilar adalimumab between April 2021 and December 2024. Outcomes were compared between patients remaining on originator and those switched to biosimilar after 16 weeks. Clinical responses were assessed using Hidradenitis Suppurativa Clinical Response 50, Hidradenitis Suppurativa Clinical Response 75, and International Hidradenitis Suppurativa Severity Scoring System 55, with time-to-event analyses evaluating loss of clinical response.

Results

Patients on originator adalimumab (n = 186) demonstrated greater proportions of clinical response than biosimilars (n = 127), with time-to-event analysis showing a significant difference between curves (100 vs 52 weeks; hazard ratio = 2.73; P < .0001). Patients switched to biosimilars (n = 71) and experienced higher rates of loss of response than those maintained on originator (n = 71) (50 vs 87 weeks; hazard ratio = 2.42; P = .0003).

Limitations

Limitations include its retrospective design and variable biosimilar formulations.

Conclusion

Significant differences in clinical response, loss of response, and time-to-event analysis between originator and biosimilar adalimumab in HS underscore the need for consistent treatment and robust monitoring to optimize management.

背景：达达木单抗是治疗化脓性汗腺炎（HS）的主要药物；然而，高成本限制了可访问性。虽然生物仿制药提供了一种负担得起的替代方案，但人们仍然担心临床等效性和转换的影响。目的评价原研药与阿达木单抗生物仿制药在HS中的临床反应，并评估非药物转换后的结局。这项多中心、真实世界的研究包括在2021年4月至2024年12月期间开始使用阿达木单抗或生物仿制药的naïve HS患者。结果比较了16周后继续使用原研药物的患者和改用生物仿制药的患者。临床反应采用化脓性汗腺炎临床反应50、化脓性汗腺炎临床反应75和国际化脓性汗腺炎严重程度评分系统55进行评估，并通过事件发生时间分析评估临床反应的丧失。结果使用原药阿达木单抗的患者（n = 186）比使用生物仿制药的患者（n = 127）表现出更大的临床反应比例，事件发生时间分析显示曲线之间存在显著差异（100周vs 52周；风险比= 2.73;P < 0.0001）。转而使用生物仿制药的患者（n = 71）比维持原药治疗的患者（n = 71）的反应丧失率更高（50周vs 87周；风险比= 2.42;P = 0.0003）。局限性包括其回顾性设计和可变的生物类似药配方。结论：阿达木单抗与原药在HS患者的临床反应、反应丧失和事件发生时间分析方面存在显著差异，因此需要一致的治疗和强有力的监测来优化管理。

{"title":"Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching","authors":"Marra Aghajani MBBS, PhD , James Pham MD , Tara Sholji MBBS , Kate Burrell BSc , Cindy Kok MD, PhD , John W. Frew MBBS (Hons), MMed, MS, PhD","doi":"10.1016/j.jdin.2025.05.023","DOIUrl":"10.1016/j.jdin.2025.05.023","url":null,"abstract":"<div><h3>Background</h3><div>Adalimumab is a mainstay treatment for hidradenitis suppurativa (HS); however, high-costs limit accessibility. While biosimilars offer an affordable alternative, concerns remain regarding clinical equivalence and the impact of switching.</div></div><div><h3>Objective</h3><div>To evaluate the clinical response of originator versus biosimilar adalimumab in HS and assess outcomes following nonmedical switching.</div></div><div><h3>Methods</h3><div>This multicenter, real-world study included treatment naïve HS patients initiated on originator or biosimilar adalimumab between April 2021 and December 2024. Outcomes were compared between patients remaining on originator and those switched to biosimilar after 16 weeks. Clinical responses were assessed using Hidradenitis Suppurativa Clinical Response 50, Hidradenitis Suppurativa Clinical Response 75, and International Hidradenitis Suppurativa Severity Scoring System 55, with time-to-event analyses evaluating loss of clinical response.</div></div><div><h3>Results</h3><div>Patients on originator adalimumab (<em>n</em> = 186) demonstrated greater proportions of clinical response than biosimilars (<em>n</em> = 127), with time-to-event analysis showing a significant difference between curves (100 vs 52 weeks; hazard ratio = 2.73; <em>P</em> < .0001). Patients switched to biosimilars (<em>n</em> = 71) and experienced higher rates of loss of response than those maintained on originator (<em>n</em> = 71) (50 vs 87 weeks; hazard ratio = 2.42; <em>P</em> = .0003).</div></div><div><h3>Limitations</h3><div>Limitations include its retrospective design and variable biosimilar formulations.</div></div><div><h3>Conclusion</h3><div>Significant differences in clinical response, loss of response, and time-to-event analysis between originator and biosimilar adalimumab in HS underscore the need for consistent treatment and robust monitoring to optimize management.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"24 ","pages":"Pages 9-15"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145398513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral tranexamic acid use for melasma is not associated with thromboembolism: Findings from a multicenter propensity score–matched electronic health record cohort 口服氨甲环酸治疗黄褐斑与血栓栓塞无关：来自多中心倾向评分匹配电子健康记录队列的研究结果

IF 5.2

JAAD International

Pub Date : 2025-09-30 DOI: 10.1016/j.jdin.2025.09.005

Tyler Hernandez MD , Kayla Penny MD , Nicholas Culotta MD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JAAD International

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀